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During the last decades, the pharmacotherapy of heart failure
(HF) has changed dramatically. Large-scale trials have been
conducted that have indisputably shown the efficacy of
angiotensin-converting enzyme inhibitors (ACE-I) and beta-
adrenergic receptor blockers (β-blockers). These and other
therapies have improved the overall outcome of patients with
HF, although prognosis remains bleak.
To identify patients with high risk for suffering a
cardiovascular event or death, numerous (bio)markers have
been put to test. (Serial) B-type natriuretic peptide (BNP)
has emerged as a powerful surrogate parameter to monitor
the severity of heart failure [1]. BNP can be measured
easily and reliably [2] and currently, BNP is generally
accepted as one of the strongest predictors for future events,
death, and its use is advocated to monitor treatment [1].
In order for us to use BNP as a surrogate parameter at
the full range of HF patients, we need to understand how
BNP is regulated and what effects different drugs exert on
BNP expression, production, and release.
BNP is expressed by ventricular, and to a lesser extent,
atrial cardiomyocytes upon stretch [1]. On a clinical level,
this is paralleled by mRNA levels that are directly related to
parameters of severity of HF and to LV geometry [3]. On a
molecular level, angiotensin II directly increases mRNA
levels of BNP via posttranscriptional control of BNP [4, 5].
This in part mediated by a GATA element in the BNP
promoter [6]. GATA elements are necessary and sufficient
to confer transcriptional activation of BNP gene in response
to hemodynamic stress [7]. So, angiotensin II seems to
bring about increased expression of BNP, and this is
paralleled with decreased BNP levels after institution of
ACE-I and/or angiotensin receptor blockade [1, 8].
The beta1-adrenergic agonistisoproterenol stimulatesBNP
promoter activity by binding of nuclear protein to a GATA
element [9]. So, do we fully understand what change in BNP
level we can expect when we start a β-blocker in HF? Not
quite. It has been observed [10, 11] that installment of the β-
blocker metoprolol treatment in HF is not associated with a
decrease in BNP levels, and in fact increases these levels.
In the current issue of the Journal, a substudy of the
CARMEN shows that treatment with the β-blocker
carvedilol alone is not associated with a decrease in BNP
levels [12], while at the same time, (NT-pro) BNP predicts
outcome. This study also shows, that treatment with an
angiotensin converting enzyme (ACE) inhibitor, either
alone or in combination with carvedilol, causes a decrease
in these peptides. The fact, that ACE inhibition lowers BNP
levels in patients with CHF has been reported before [13],
as the authors point out, but a direct comparison between
the two drugs and their combination on BNP levels present
novel data.
The present study is therefore important for more than
one reason. First, it shows that we should realize that there
is an uncoupling of BNP levels and prognosis in HF
patients who have been put on β-blockade just recently. It
is beyond any doubt that β-blockers improve prognosis in
patients with HF, but is also beyond any doubt that BNP
levels reflect clinical status and prognosis in HF as well.
What does this mean? It means that we should realize that a
modest, transient increase in BNP levels should be accepted
and regarded as a possible “side-effect” of β-blockade.
There is work to do in determining how long this BNP
increase lasts and what level of increase is still acceptable.
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the CARMEN provides more data on whether treatment for
HF might be initiated also with a beta-blocker instead of an
ACE inhibitor [14]. It is common practice to start treatment
of HF with an ACE-I and then add a β-blocker soon, and
then other drugs [15]. This is because the large-scale trials
have been conducted in this order and this is also advocated
by HF guidelines. While there can be no discussion that the
combination of an ACE inhibitor and a beta-blocker is by far
the most effective drug regimen [16], the truth is that it often
takes a long time after initiation of the first drug before the
second drug is started. In addition, the first drug more often
is uptitrated to the target dose, while the second drug is
usually not. It is therefore important to analyze available data
on this issue, and there are now three studies that have
challenged this paradigm.
In the CARMEN (main) study [17], which examined the
effects of drug therapy on left ventricular (LV) dilatation,
combination therapy of an ACE inhibitor and a beta-blocker
had the most pronounced effect on LV function, but beta-
blockade alone was at least as effective as ACE inhibition
alone. In the second study by Sliwa et al. [18] the beta-
blocker carvedilol was in fact more beneficial than the ACE
inhibitor with regard to exercise performance, functional
class, but also N-BNP levels. In the largest comparative
study so far, CIBIS-III [19], initiation of the beta-blocker
bisoprolol for 6 months followed by 12 months combination
therapy with an ACE inhibitor, was as effective as 6 months
monotherapy with ACE inhibition, followed by another
12 months with the combination. Interestingly, in CIBIS-III
beta-blockade was associated with slightly fewer sudden
deaths, while slightly more patients had progression of HF,
although neither of these effects was statistically significant.
The present data, i.e. the fact that beta-blockade alone leads
to an increase in BNP levels, may therefore be important in
the light of these findings from CIBIS-III, since the two
findings appear to be compatible. While it cannot be
excluded that in CARMEN (and in CIBIS for that matter),
uptitration of beta-blockade may have been “too much, too
quick” (leading to increases in BNP and possibly to
worsening HF), concurrent use of an ACE inhibitor is
needed, as was again shown in the present study [12].
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